Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
4,766
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
stocks
ASX share ticks all the popular thematic boxes
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.80 | 0.10 | 0.00% |
| CAC 40 | 8,384.39 | 37.19 | 0.45% |
| DAX 40 | 25,391.88 | 28.78 | -0.11% |
| Dow JONES (US) | 49,191.99 | 398.21 | -0.80% |
| FTSE 100 | 10,162.74 | 25.39 | 0.25% |
| HKSE | 26,999.81 | 151.34 | 0.56% |
| NASDAQ | 23,709.87 | 24.03 | -0.10% |
| Nikkei 225 | 54,341.23 | 792.07 | 1.48% |
| NZX 50 Index | 13,757.71 | 101.66 | 0.74% |
| S&P 500 | 6,963.74 | 13.53 | -0.19% |
| S&P/ASX 200 | 8,820.60 | 1.20 | -0.01% |
| SSE Composite Index | 4,126.09 | 12.67 | -0.31% |